Cell transplantation and inflammation
细胞移植与炎症
基本信息
- 批准号:9135743
- 负责人:
- 金额:$ 18.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-21 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Liver-directed cell/gene therapy is of enormous significance for many genetic, metabolic and acquired conditions that may cause injury and/or adverse effects in the liver or multiple other target organs. Based on work in our and other laboratories over the past 25 years, hepatocyte transplantation has been performed in some 100 people with various conditions. These studies indicated that insights from rodent models were appropriate and predicted clinical outcomes in people after cell/gene therapy. Moreover, initial experiences of cell therapy in people established the need for returning to studies in animals, particularly to define mechanisms in engraftment of transplanted cells that could advance liver repopulation to achieve superior therapeutic outcomes. In more recent studies, it was shown that transplanted cells engrafted in the liver through multi-step processes. For instance, after deposition in liver sinusoids, transplanted hepatocytes engrafted in liver parenchyma, whereas after injection into the hepatic artery, transplanted hepatocytes were promptly destroyed. Entry of transplanted cells in the liver parenchyma required disruption of sinusoidal endothelial barrier, so that cells could travel through the space of Disse, followed by liver remodeling to accept transplanted cells in the parenchymal structure. However, cell transplantation induced ischemia and tissue injury, leading to recruitment of inflammatory cells in the setting of syngeneic or autologous cells, and of professional immunocytes, in the setting of allogeneic cells, along with activation of liver sinusoidal endothelial cells and hepatic stellate cells. Cell-cell interactions in the liver could be beneficial, e.g., disruption of liver sinusoidal endothelial cells improved engraftment of transplanted cells and beneficial activation of hepatic stellate cells released cytoprotective factors and promoted matrix remodeling, again with superior cell engraftment. Or cell-cell interactions could be deleterious. For instance, release of inflammatory cytokines and chemokines resulted in clearance of significant fractions of transplanted cells over several hours, while activation of additional adaptive immune responses against allogeneic cells, led to the clearance of cells over several days. As suitable interventions could alter these initial cell losses, we will address the hypothesis that insights into mechanisms of cell transplantation-induced liver inflammation and its effects on cell engraftment will help obtain effective pharmacological approaches for advancing cell/gene therapy. To understand the nature of cellular perturbations, we will perform studies in superb rodent models and define inflammatory cell-specific changes, including mechanisms in relevant cytokine-chemokine activations, as well as cell-cell interactions. We will perform pharmacological studies with clinically-relevant drugs to block undesirable mechanisms for improving engraftment of transplanted cells. Moreover, we will examine the efficacy of these manipulations for liver repopulation and cell therapy in further animal models. Taken together, this proposal will advance novel insights for liver-directed cell/gene therapy and will be of extensive significance for human health.
描述(由申请人提供):肝脏定向细胞/基因治疗对于许多可能导致肝脏或多个其他靶器官损伤和/或不良反应的遗传、代谢和获得性疾病具有巨大意义。基于我们和其他实验室在过去25年中的工作,肝细胞移植已在约100名患有各种疾病的患者中进行。这些研究表明,啮齿动物模型的见解是适当的,并预测了细胞/基因治疗后的临床结果。此外,人类细胞治疗的初步经验确立了回归动物研究的必要性,特别是确定移植细胞植入的机制,这些机制可以促进肝脏再增殖,以实现上级治疗结果。在最近的研究中,研究表明移植细胞通过多步骤过程植入肝脏。例如,在肝窦中沉积后,移植的肝细胞在肝实质中植入,而在注射到肝动脉中后,移植的肝细胞迅速被破坏。移植细胞进入肝实质需要破坏窦状内皮屏障,使细胞可以通过Disse空间,然后进行肝脏重建,以接受肝实质结构中的移植细胞。然而,细胞移植诱导缺血和组织损伤,导致在同基因或自体细胞的情况下炎症细胞的募集,以及在同种异体细胞的情况下专职免疫细胞的募集,沿着肝窦内皮细胞和肝星状细胞的活化。肝脏中的细胞-细胞相互作用可能是有益的,例如,肝窦内皮细胞的破坏改善了移植细胞的植入,并且肝星状细胞的有益活化释放了细胞保护因子并促进了基质重塑,再次具有上级细胞植入。或者细胞间的相互作用可能是有害的。例如,炎性细胞因子和趋化因子的释放导致移植细胞的显著部分在数小时内被清除,而针对同种异体细胞的额外适应性免疫应答的激活导致细胞在数天内被清除。由于适当的干预措施可以改变这些初始的细胞损失,我们将解决这一假设,即深入了解细胞移植诱导的肝脏炎症机制及其对细胞植入的影响将有助于获得有效的药理学方法,以推进细胞/基因治疗。为了了解细胞扰动的性质,我们将在极好的啮齿动物模型中进行研究,并定义炎症细胞特异性变化,包括相关的趋化因子激活机制以及细胞间相互作用。我们将使用临床相关药物进行药理学研究,以阻断不良机制,改善移植细胞的植入。此外,我们将在进一步的动物模型中检查这些操作对肝脏再生和细胞治疗的功效。总之,这一提议将为肝脏定向细胞/基因治疗提出新的见解,并将对人类健康具有广泛的意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SANJEEV GUPTA其他文献
SANJEEV GUPTA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SANJEEV GUPTA', 18)}}的其他基金
相似国自然基金
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
- 批准号:82371726
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
骨髓抑制再生单个核细胞移植通过调节线粒体功能在脑缺血再灌注损伤中的神经保护机制研究
- 批准号:82371301
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
CD27-CD28-CD8+T细胞调控儿童肝脏移植免疫耐受形成的作用和机制
- 批准号:82371791
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
人胆囊源CD63+细胞的干性特征与分化特性的研究
- 批准号:31970753
- 批准年份:2019
- 资助金额:52.0 万元
- 项目类别:面上项目
亚硝酸钠对肝移植物缺血再灌注损伤的保护作用及其机制
- 批准号:81170416
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
肠上皮内γδT细胞诱导抗原特异性Treg的体内机制及其对肾移植慢性排斥的抑制作用研究
- 批准号:81170693
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
缺氧预处理调节骨髓源性间充质干细胞归巢能力对兔急性缺血性肾损伤修复的影响
- 批准号:81000307
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
超顺磁性氧化铁-量子点双显像荷电量可控性正电荷纳米囊泡用于干细胞移植的MRI活体示踪
- 批准号:81071208
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
荷人卵巢上皮癌裸鼠冻融卵巢组织移植的安全性研究
- 批准号:30960408
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
骨髓间充质干细胞向肝脏星状细胞定向分化的构建及其在诱导同种异体胰岛细胞移植免疫耐受中的作用
- 批准号:30872484
- 批准年份:2008
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
Regulation and function of aged hematopoietic stem cell (HSC) niche
衰老造血干细胞(HSC)生态位的调节和功能
- 批准号:
10723396 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Investigating hematopoietic stem cell dysfunction during sickle cell disease
研究镰状细胞病期间的造血干细胞功能障碍
- 批准号:
10681829 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Mapping Integrated Single-Cell Chromatin Accessibility with the Single-Cell Transcriptional Landscape in Pediatric Type 2 Diabetes
绘制儿科 2 型糖尿病中单细胞染色质可及性与单细胞转录景观的整合图谱
- 批准号:
10664557 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Developing novel therapies to improve blood stem cell transplantation outcomes
开发新疗法以改善造血干细胞移植结果
- 批准号:
10830194 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Prohibiting Cell Death in Human Keratocytes: New Insights for Non-surgical Keratoconus Treatment
抑制人角膜细胞的细胞死亡:非手术圆锥角膜治疗的新见解
- 批准号:
10720431 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Study of the Safety, Tolerability, and Efficacy of an iPS Cell-based Therapy for Recessive Dystrophic Epidermolysis Bullosa Delivered with a Spray on Skin Device
使用皮肤喷雾装置治疗隐性营养不良性大疱性表皮松解症的 iPS 细胞疗法的安全性、耐受性和有效性研究
- 批准号:
10721324 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
The Role of Hsf1 in Hematopoietic Stem Cell Aging
Hsf1在造血干细胞衰老中的作用
- 批准号:
10749675 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Human Schwann Cell-Derived Exosome Treatment for Traumatic Brain Injury
人雪旺细胞衍生的外泌体治疗创伤性脑损伤
- 批准号:
10714644 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Endogenous memory T cell mediated rejection of high-risk cardiac allografts
内源性记忆T细胞介导的高风险同种异体心脏移植排斥反应
- 批准号:
10748492 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:














{{item.name}}会员




